A method for purifying ulinastatin

By employing an online real-time control mechanism and a segmented processing strategy, the challenges of achieving high purity and high yield in ulinastatin ion exchange chromatography were solved, resulting in improved product purity and yield, as well as enhanced raw material utilization and the environmental friendliness of the process.

CN123106884APending Publication Date: 2026-11-17KUNMING XUFENG BIOPHARMACEUTICAL CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202611404077.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-10
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing ion exchange chromatography purification methods for ulinastatin are difficult to achieve simultaneously with high purity and high yield, and lack real-time control over the quantitative properties of the target protein, resulting in inconsistencies between product purity and yield.

Method used

An online, real-time, and precise control mechanism is adopted. Peak boundaries are determined by the first and second derivatives of UV absorbance, and combined with the degree of glycosylation detection, to achieve automated and precise collection of the main elution peak and directional recovery of transition fractions. Each fraction is processed in stages to ensure product quality and yield.

Benefits of technology

This approach achieves both high purity and high yield of ulinastatin, ensuring consistent product quality. Furthermore, it improves raw material utilization through waste liquid reuse and re-chromatographic treatment, aligning with the development direction of green pharmaceuticals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106884A_ABST
    Figure CN123106884A_ABST
Patent Text Reader

Abstract

This invention discloses a method for purifying ulinastatin, belonging to the field of protein purification technology. The method includes: concentrating the crude ulinastatin extract through microfiltration and ultrafiltration, followed by anion exchange chromatography. During elution, UV absorbance is collected in real time, and the first / second derivatives are calculated to determine peak boundaries. Simultaneously, online sampling is performed to detect the glycosylation level of the eluent at a timescale based on the main elution peak. Collection is only initiated when the starting point has been determined and the glycosylation level meets the standard. The main peak eluent is collected as the first-stage purified product, while the leading and trailing transition fractions are collected separately. After concentration and specific activity screening, a second-stage chromatographic purification is performed, and the purified fractions are merged with the main peak. Unqualified products are recycled; if unqualified after three cycles, they are discarded. This invention achieves a balance between high purity and high yield through a dual confirmation mechanism and three-stage collection, with good batch-to-batch consistency, making it suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of protein purification technology, and more specifically, to a method for purifying ulinastatin. Background Technology

[0002] Ulinastatin (also known as urinary trypsin inhibitor, UTI) is an acidic glycoprotein extracted from the urine of healthy individuals. It consists of 143 amino acids, has a molecular weight of approximately 67 kDa, and an extremely low isoelectric point (pI approximately 2–3.5). Ulinastatin can broadly inhibit the activity of various proteases (such as trypsin, chymotrypsin, and elastase) and is widely used clinically to treat acute pancreatitis, chronic relapsing pancreatitis, and acute circulatory failure.

[0003] Currently, purification methods for ulinastatin mainly include hydrophobic column chromatography, affinity chromatography, ion exchange chromatography, chitin adsorption, and ammonium sulfate precipitation. For example, Chinese patent CN103073637B discloses a method for purifying ulinastatin using adsorption column chromatography; Chinese patent application CN116355078A discloses a purification method and product for ulinastatin, which uses a series of anion exchange and cation exchange chromatography to purify ulinastatin; Chinese patent CN107827976B discloses a purification method for ulinastatin based on a hydrophobic column; and Chinese patent application CN108059670A discloses a purification method for ulinastatin based on an affinity chromatography column. These methods typically employ multi-step tandem chromatography, resulting in long process chains, complex operations, and high production costs.

[0004] Ion exchange chromatography is one of the most commonly used techniques for purifying ulinastatin. However, existing ulinastatin ion exchange chromatography purification methods suffer from a fundamental contradiction that has long remained unresolved: pursuing high purity inevitably leads to a decrease in yield, while pursuing high yield inevitably sacrifices purity. Specifically: (i) The collection boundary of the elution peak relies on manual experience and lacks precise online real-time control. During ion exchange chromatography elution, the elution peak of the target protein usually exhibits asymmetry (steep leading edge and long tail). Current techniques typically rely on operators' manual judgment based on changes in the UV detector signal to determine when to start and stop collection. Inconsistent judgment criteria between different operators and between different batches result in the main peak being either cut too wide (introducing impurities and reducing purity) or too narrow (losing the target protein and reducing yield). This problem is particularly prominent in the purification of ulinastatin (whose extremely low isoelectric point causes significant peak tailing).

[0005] (ii) The transition fractions at the leading and trailing ends of the elution peak lack sophisticated sorting and recovery strategies. In existing technologies, the transition fractions located at the leading and trailing ends of the main peak (containing the target protein but with lower purity) are usually discarded as a whole (resulting in yield loss) or directly mixed with the main peak (resulting in decreased purity). Existing technologies lack sophisticated sorting strategies and targeted recovery mechanisms for the transition fractions, making it impossible to fully recover ulinastatin from the transition fractions while ensuring the purity of the main peak.

[0006] (iii) The control signal for fraction collection is singular and does not consider the quality attributes of the target protein. Current technologies primarily rely on a single UV absorbance signal to trigger fraction collection, failing to incorporate key quality attributes such as the degree of glycosylation of the target protein into the collection decision. Ulinastatin, as a glycoprotein, has its specific activity and in vivo half-life directly affected by its degree of glycosylation. Relying solely on the UV absorbance signal cannot ensure that the collected target component meets pharmaceutical requirements in terms of quality attributes.

[0007] Furthermore, in the field of chromatographic data processing, there are existing technical solutions that utilize first and second derivatives to identify chromatographic peak inflection points (such as the US patent application with publication number US20140149050A1) or peak apexes (such as the Chinese patent with publication number CN111767790B). However, these solutions all belong to the field of post-processing data analysis: that is, identifying peak positions offline from stored chromatographic data for calculating column performance indicators such as theoretical plate number, without involving real-time process control, let alone using the identification results for real-time switching of fraction collection valves during chromatographic purification.

[0008] Therefore, how to achieve the goal of "high purity and high yield" in the ion exchange chromatography purification of ulinastatin through online real-time precise control, while ensuring the consistency of product quality attributes, remains a technical challenge that urgently needs to be solved in this field. Summary of the Invention

[0009] To address the shortcomings of existing ulinastatin ion exchange chromatography purification methods, which struggle to achieve both high purity and high yield, this invention provides a purification method for ulinastatin. This method establishes an online, real-time, and precise control mechanism during the chromatographic elution process, enabling automated and accurate determination of the elution peak boundary and targeted recovery of transition fractions. This significantly improves the overall purification yield while ensuring product purity meets pharmaceutical standards, and simultaneously guarantees batch-to-batch product quality consistency.

[0010] To achieve the above objectives, the present invention provides a method for purifying ulinastatin, comprising the following steps: S1: The crude extract of ulinastatin is subjected to microfiltration to remove suspended solids and macromolecular impurities, resulting in a clear filtrate.

[0011] S2: The clarified filtrate is concentrated by ultrafiltration. The pH and conductivity of the retentate are monitored online in real time. When the pH and conductivity of the retentate simultaneously meet the loading parameters of anion exchange chromatography, the concentration is stopped, and the chromatographic loading solution is obtained.

[0012] S3: Load the chromatographic sample solution onto the anion exchange chromatography medium. Use a pH-salt concentration dual gradient stepwise elution method to remove impurity protein components in stages, and then collect the ulinastatin target component. During the elution process, collect the UV absorbance data at the column outlet in real time and calculate its first and second derivatives. Determine the start point, peak, and end point of the elution peak in real time based on the rate of change of the first and second derivatives. Simultaneously, take online samples periodically on the time scale of the elution peak to detect the glycosylation degree of the eluent. When the start point has been determined and the glycosylation degree reaches the preset glycosylation degree threshold, start the collection of the target component. When the end point is determined, stop the collection.

[0013] S4: Taking the start of target component collection in step S3 as the starting point of main peak collection and the end point as the end point of main peak collection, the main peak eluent is collected as the first-stage purified product; the eluent from the starting point to the start of main peak collection is collected separately as the leading transition fraction; the eluent from the end point to the point where the absolute value of the first derivative is continuously lower than the third preset threshold for more than 3 sampling cycles is collected separately as the tail transition fraction.

[0014] S5: The leading transition fraction and the tail transition fraction are concentrated separately, and the specific activity of ulinastatin in the concentrate is measured. When the specific activity is not lower than the preset specific activity threshold, the fraction is purified by chromatography under the second chromatography conditions, and the leading re-chromatographic product and the tail re-chromatographic product are collected separately.

[0015] S6: Detect the purity of the frontal re-chromatographic product and the tail re-chromatographic product. When the purity of both is not lower than the preset purity threshold, combine the first-stage purified product, the frontal re-chromatographic product, and the tail re-chromatographic product to obtain pure ulinastatin. Otherwise, use the unqualified re-chromatographic product as the raw material for step S5 for re-chromatographic purification. If the purity is still unqualified after three consecutive re-chromatographic purifications, discard the product.

[0016] Preferably, the loading parameters for anion exchange chromatography in step S2 are: pH value 5.0-5.5, conductivity 8-12 mS / cm; ultrafiltration adopts constant pressure operation mode, with an operating pressure of 0.15-0.25 MPa and an ultrafiltration membrane molecular weight cutoff of 10-30 kDa.

[0017] Preferably, step S3, the pH-salt concentration dual-gradient stepwise elution, specifically includes three stages: The first stage of impurity removal involves elution with an acetate-sodium acetate buffer solution at pH 5.0–5.5 and a sodium chloride concentration of 0.05–0.1 mol / L to remove the first type of impurities. The second stage of impurity removal involves elution with an acetate-sodium acetate buffer solution at a pH of 4.2–4.8 and a sodium chloride concentration of 0.15–0.2 mol / L to remove the second type of impurities. The third stage of collection: Elution was performed using an acetate-sodium acetate buffer solution with a pH of 3.5–4.0 and a sodium chloride concentration of 0.3–0.5 mol / L, and the eluent of the ulinastatin target peak was collected.

[0018] Preferably, the glycosylation threshold in step S3 is 12%.

[0019] Preferably, the second chromatography conditions in step S5 are: the sample loading amount is 30% to 150% of the sample loading amount in step S3, and the eluent volume in each stage is 50% to 100% of the eluent volume in the corresponding stage in step S3.

[0020] Preferably, in step S5, the preset specific activity threshold is 85% of the specific activity of ulinastatin in the clarified filtrate; the concentration treatment increases the concentration of ulinastatin to 2 to 5 times the original concentration.

[0021] Preferably, the method further includes hydrophobic chromatography purification of the first-stage purified product collected in step S4: after adjusting the ammonium sulfate concentration to 1.2-1.5 mol / L, the sample is loaded onto phenyl agarose gel chromatography medium, eluted using a gradient desalting method, and the active elution peak of ulinastatin is collected; and the active elution peak is used to replace the first-stage purified product collected in step S4 for the merging operation in step S6.

[0022] Preferably, the method further includes combining the eluent of the impurity proteins generated in the elution stage of removing impurity proteins in step S3 with the column regeneration waste liquid, enriching the ulinastatin therein through a nanofiltration membrane, and returning the enriched solution to the clarified filtrate of step S1 for recycling; the molecular weight cutoff of the nanofiltration membrane is 3-5 kDa; the nanofiltration permeate is desalted by reverse osmosis and used to prepare the elution buffer of step S3.

[0023] Preferably, in step S6, the preset purity threshold is 90% of the purity of the first-stage purified product; the purity is the peak area normalized purity measured by high-performance liquid chromatography.

[0024] Preferably, the method for determining the starting point, peak apex, and ending point in step S3 is as follows: When the first derivative increases from a value less than the first preset threshold to a positive value greater than the first preset threshold, and the second derivative is greater than the second preset threshold, it is determined to be the starting point; When the first derivative decreases from a positive value to a negative value, and the second derivative is less than 0, it is determined to be a peak. When the first derivative increases from a negative value less than the third preset threshold to a value greater than the third preset threshold, and the second derivative changes from a negative value to a positive value, it is determined to be the termination point; The sampling frequency of ultraviolet absorbance is 2 to 10 times per second.

[0025] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention employs both UV first / second derivatives to determine peak boundaries in real time and performs online sampling and detection of glycosylation levels during chromatographic elution, forming a dual confirmation mechanism of "geometric boundary determination + quality attribute confirmation." UV first / second derivatives provide millisecond-level continuous peak shape monitoring for real-time peak boundary determination; glycosylation level detection provides confirmation of quality attributes. These two mechanisms complement each other in the temporal dimension: UV derivatives handle real-time continuous monitoring, while glycosylation level detection provides periodic quality confirmation, together forming a complete "sensing → confirmation" chain. Target component collection is only initiated when peak boundaries have been determined and the glycosylation level reaches a preset threshold. This mechanism avoids misjudgments based on a single UV signal, ensuring that the collected target components meet requirements in both purity and quality attributes.

[0026] 2. This invention finely divides the elution peak into three functionally distinct segments: a leading transition fraction, the main peak, and a trailing transition fraction, which are collected and processed separately. The main peak is directly used as the first-stage purification product; the leading and trailing transition fractions are concentrated and screened for specific activity before undergoing second-stage chromatographic purification, and are then combined with the main peak after reaching the required standards. This "three-stage" strategy differs from the traditional "whole-segment collection" or "fixed-volume segmentation," achieving the dual goals of "high purity of the main peak + high recovery of the transition fraction."

[0027] 3. This invention incorporates a purity detection step after the transition fraction re-chromatography: products meeting the purity standard are merged with the main peak, while substandard products are returned for re-chromatography; if substandard products fail three consecutive times, they are discarded. This mechanism ensures that the purity of the final product is not lower than the preset standard while avoiding the inability to terminate the process due to "infinite loops." Simultaneously, using an "85% specific activity threshold" as the entry standard for re-chromatography ensures that only transition fractions with good activity retention enter the re-chromatography process, avoiding the waste of production capacity caused by "blindly recovering inactivated proteins."

[0028] 4. This invention couples an online real-time detection-driven control loop (ultrafiltration pH / conductivity reaching the target triggers sample loading → UV / glycosylation degree dual confirmation triggers peak cutting → termination point triggers collection stop) with a material recovery loop (three-stage segmented collection → transition fraction concentration → specific activity screening → re-chromatography → purity threshold merging / recycling). The control loop ensures accurate division of the main peak and transition fraction, while the material loop ensures efficient recovery of ulinastatin from the transition fraction. A single loop cannot achieve the dual breakthrough of "high purity + high yield": with only a control loop and no material loop, the target protein in the transition fraction will be lost; with only a material loop and no control loop, too many impurities will be mixed into the transition fraction, resulting in poor re-chromatography performance. In this invention, the two loops are coupled and linked through the same detection-judgment unit (UV derivative + glycosylation degree), forming a complete process loop of "detection → judgment → execution → recovery → re-detection," achieving a synergistic effect that cannot be achieved by a single feature.

[0029] 5. This invention combines the eluent containing extraneous proteins generated during chromatography with the column regeneration waste liquid. Trace amounts of ulinastatin are then enriched using a nanofiltration membrane and returned to the front end of the process for recycling. Simultaneously, the nanofiltration permeate is desalted via reverse osmosis and reused to prepare the elution buffer. This waste liquid reuse scheme not only improves raw material utilization but also reduces waste liquid discharge and the consumption of fresh buffer, aligning with the development direction of green pharmaceuticals.

[0030] 6. Each step of the method of the present invention uses mature industrial chromatography equipment and online detection system, which has good feasibility for large-scale production and can be applied to the industrial-scale production of ulinastatin. Attached Figure Description

[0031] Figure 1 This is a flowchart of the overall process flow of the purification method of the present invention. Detailed Implementation

[0032] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments and comparative examples. It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the scope of protection of this invention. Experimental methods not specifying specific conditions in the embodiments are generally performed under conventional conditions or as recommended by the manufacturer.

[0033] In the following examples, the crude ulinastatin extract was obtained from the urine of healthy adult males after chitin adsorption, ammonia elution, and ammonium sulfate precipitation, and was then dissolved in purified water. The anion exchange chromatography medium was QSepharose Fast Flow (GE Healthcare); the ultrafiltration membrane was a Pellicon 3 ultrafiltration membrane pack (Millipore) with a molecular weight cutoff of 10 kDa; the degree of glycosylation was determined using hydrophilic interaction chromatography-fluorescence detection (HILIC-FLD), with a detection cycle of approximately 3 minutes. In this invention, the degree of glycosylation refers to the relative content of glycosylated modifications in the ulinastatin molecule, expressed as the percentage of glycosylated peak area measured by the HILIC-FLD method. Ulinastatin specific activity was determined using the substrate enzymatic digestion method as described in the Chinese Pharmacopoeia, expressed as trypsin inhibitor units per milligram of protein (TIU / mg). TIU (Trypsin Inhibitor Unit) is equivalent to the ulinastatin activity unit specified in the Chinese Pharmacopoeia. Purity was determined by high performance liquid chromatography (HPLC) with peak area normalized purity.

[0034] Example 1 Please see Figure 1 This embodiment provides a method for purifying ulinastatin using the complete scheme of the present invention.

[0035] S1: Take 10L of crude ulinastatin extract and microfilter it through a 0.45μm microporous membrane to remove suspended solids and macromolecular impurities, and obtain 9.5L of clear filtrate.

[0036] S2: The clarified filtrate is concentrated by cross-flow ultrafiltration through an ultrafiltration membrane with a molecular weight cutoff of 10 kDa, using a constant pressure operation mode at a pressure of 0.2 MPa. During the concentration process, the pH and conductivity of the retentate are monitored online in real time. When the pH of the retentate drops to the range of 5.0–5.5 and the conductivity drops to the range of 8–12 mS / cm, the concentration is automatically stopped, yielding 1.5 L of chromatographic loading solution.

[0037] S3: Load the chromatography sample solution onto a Q Sepharose Fast Flow anion exchange chromatography column (column volume 2.5L). First, equilibrate the column with equilibration buffer (pH 5.5, 10mM acetate-sodium acetate buffer), then elute using a pH-salt concentration dual gradient stepwise elution method: First stage of impurity removal: Elute for 2 column volumes with acetate-sodium acetate buffer at pH 5.5 and sodium chloride concentration of 0.05 mol / L to remove the first type of impurities; The second stage of impurity removal: three column volumes of acetate-sodium acetate buffer solution with pH 4.5 and sodium chloride concentration of 0.15 mol / L were used to remove the second type of impurity proteins. Third stage collection: Elute four column volumes with an acetate-sodium acetate buffer solution at pH 3.8 and a sodium chloride concentration of 0.4 mol / L to collect the ulinastatin target fraction.

[0038] During the third-stage elution process, the UV absorbance A at the column outlet was collected in real time at a sampling frequency of 5 times / second. 280 Data, calculate the first derivative dA / dt and the second derivative d 2 A / dt 2 The first preset threshold is set to 2.0 mAU / s, the second preset threshold is set to 2.0 mAU / s, and the third preset threshold is set to 0.5 mAU / s. When the first derivative increases from a value less than 2.0 mAU / s to a positive value greater than 2.0 mAU / s, and the second derivative is greater than 2.0 mAU / s, the starting point T1 of the elution peak is determined; when the first derivative decreases from a positive value to a negative value, and the second derivative is less than 0, the peak is determined to be T3; when the first derivative increases from a negative value less than 0.5 mAU / s to a value greater than 0.5 mAU / s, and the second derivative changes from a negative value to a positive value, the termination point T4 is determined. Simultaneously, online sampling is performed to detect the degree of glycosylation in the eluent at a time scale equal to the time scale of the chromatographic elution peak (detection cycle approximately 3 minutes). When the starting point T1 has been determined and the degree of glycosylation reaches 12%, the collection of the target component is started (main peak collection starting point T2); when the termination point T4 is determined, the collection is stopped.

[0039] In addition, this embodiment also treats the eluent and column regeneration waste generated in step S3, which is used to remove impurities: ulinastatin is enriched by using a nanofiltration membrane with a molecular weight cutoff of 3-5 kDa, and the enriched solution is returned to the clarified filtrate of step S1 for recycling; the nanofiltration permeate is desalted by reverse osmosis and used to prepare the elution buffer for step S3.

[0040] S4: Using the start point of target component collection (T2) as the starting point of main peak collection and the end point (T4) as the end point of main peak collection, the main peak eluent (between T2 and T4) is collected as the first-stage purified product, with a volume of 2.8 L. The eluent from the starting point T1 to the main peak collection starting point T2 is collected separately as the leading transition fraction; the eluent from the end point T4 until the absolute value of the first derivative is continuously lower than the third preset threshold of 0.5 mAU / s for more than 3 sampling cycles is collected separately as the tail transition fraction. In this embodiment, the sampling frequency is 5 times / second, and one sampling cycle is 0.2 seconds, that is, the absolute value of the first derivative must be continuously lower than 0.5 mAU / s for more than 0.6 seconds.

[0041] S5: The leading and trailing transition fractions were concentrated using ultrafiltration membranes with a molecular weight cutoff of 10 kDa, increasing the concentration of ulinastatin to three times its original value. The specific activity of ulinastatin in the concentrates was determined; the specific activity of the leading transition fraction concentrate was 88% of that of the clarified filtrate, and the specific activity of the trailing transition fraction concentrate was 86% of that of the clarified filtrate, both not lower than the preset specific activity threshold of 85%. The two concentrates were then purified by chromatography under the second chromatographic conditions (using the same chromatographic medium and buffer system as in step S3, with a sample loading volume of 80% of the initial chromatographic loading volume and an eluent volume of 80% of the corresponding initial volume for each stage), and the leading and trailing re-chromatographic products were collected separately.

[0042] S6: The peak area normalized purity of the leading and trailing re-chromatographic products was determined by high-performance liquid chromatography (HPLC). The purity of the leading re-chromatographic product was 94% of the purity of the first-stage purified product, and the purity of the trailing re-chromatographic product was 92% of the purity of the first-stage purified product, both not lower than the preset purity threshold of 90%. The first-stage purified product collected in step S4 was purified by hydrophobic chromatography: after adjusting the ammonium sulfate concentration to 1.3 mol / L, the sample was loaded onto phenyl agarose gel chromatography medium (PhenylSepharose 6 Fast Flow, column volume 1.0 L), and eluted using a gradient desalting method (ammonium sulfate concentration linearly decreased from 1.3 mol / L to 0 mol / L, elution volume 5 column volumes), collecting the active elution peak of ulinastatin. This active elution peak replaced the first-stage purified product collected in step S4, and the merging operation in step S6 was performed. After ultrafiltration desalting and freeze-drying, pure ulinastatin was obtained.

[0043] The HPLC purity of the ulinastatin obtained in this example was 99.6%, the specific activity was 5250 TIU / mg protein, and the total yield was 89.8% (based on the total activity of ulinastatin in the initial crude extract).

[0044] Example 2 This embodiment provides a method for purifying ulinastatin using the basic scheme of this invention (excluding hydrophobic chromatography purification).

[0045] S1 to S6 are the same as in Example 1.

[0046] The difference from Example 1 is that the hydrophobic chromatography purification step is not performed. That is, the first-level purified product obtained in step S4 directly enters step S6 to participate in the merging without undergoing hydrophobic chromatography purification.

[0047] The HPLC purity of the ulinastatin obtained in this example was 99.2%, with a specific activity of 5100 TIU / mg protein and a total yield of 91.5%. The results indicate that the basic protocol can obtain ulinastatin with a purity ≥99% and a specific activity ≥5100 TIU / mg protein, meeting pharmaceutical grade requirements. The hydrophobic chromatography purification step added in Example 1 can further improve the purity to over 99.5%, making it suitable for product specifications with higher purity requirements.

[0048] Example 3 This embodiment provides a method for purifying ulinastatin using another preferred embodiment of the present invention (including hydrophobic chromatography purification with different parameters).

[0049] S1 to S5 are the same as in Example 1.

[0050] The difference from Example 1 is as follows: After adjusting the ammonium sulfate concentration to 1.2 mol / L, the first-stage purified product collected in step S4 was loaded onto phenyl agarose gel chromatography medium (Phenyl Sepharose 6 Fast Flow, column volume 1.0 L). A gradient desalting method was used (ammonium sulfate concentration linearly decreased from 1.2 mol / L to 0 mol / L, elution volume 6 column volumes) to elute, and the active elution peak of ulinastatin was collected. This active elution peak replaced the first-stage purified product collected in step S4, and the merging operation in step S6 was performed.

[0051] The HPLC purity of the ulinastatin obtained in this embodiment was 99.4%, the specific activity was 5180 TIU / mg protein, and the total yield was 90.2%. The results indicate that adding a hydrophobic chromatography purification step to the basic scheme can significantly improve the product purity to over 99%, and good purification results can be obtained with different purification parameters (ammonium sulfate concentration 1.2–1.5 mol / L, elution volume 5–6 column volumes), demonstrating the parameter adaptability of the preferred scheme of this invention.

[0052] Comparative Example 1 This comparative example uses the same raw materials and chromatography conditions as Example 2, but the starting point and ending point of the elution peak are determined by the operator based on the signal changes of the UV detector, without the use of online real-time derivative monitoring and dual confirmation mechanism for glycosylation degree.

[0053] Specifically: the operator observes the signal curve of the ultraviolet detector and, based on experience, determines the rising point of the peak front as the collection start point and the falling point of the peak tail as the collection end point, without performing first / second derivative calculations or glycosylation degree detection. The division of the three-stage fraction also relies on manual judgment, that is, manually determining the positions of the starting point T1, the main peak collection start point T2, and the ending point T4.

[0054] The HPLC purity of the ulinastatin obtained in this comparative example was 96.8%, with a specific activity of 4680 TIU / mg protein and a total yield of 82.3%. Compared with Example 2, both purity and yield decreased significantly, and the batch-to-batch relative standard deviation (RSD, n=5) was 4.7%, much higher than the 1.2% of Example 2. The results indicate that the online real-time monitoring and automated control mechanism adopted in this invention significantly improves the accuracy of main peak collection and batch-to-batch consistency compared to traditional manual judgment, while also enhancing product purity and yield.

[0055] Comparative Example 2 This comparative example uses the same raw materials and chromatography conditions as Example 2, but the collection of the elution peak relies solely on the first / second derivative of UV chromatography (start point T1 and end point T4), and does not use the degree of glycosylation as a dual confirmation condition for collection initiation. That is, collection is started as soon as the start point T1 is determined to be timely, rather than waiting for the degree of glycosylation to reach the target before starting.

[0056] The HPLC purity of the ulinastatin obtained in this comparative example was 97.5%, with a specific activity of 4820 TIU / mg protein and a total yield of 90.8%. Compared with Example 2, the yield was similar, but the purity and specific activity were significantly lower. The reason for this was that when relying solely on UV derivatives to determine the start of collection, the main peak collection starting point T2 shifted to T1, causing some lower-purity peak-front material to be mixed into the main peak, thus reducing the product purity. The results indicate that the degree of glycosylation, as a dual confirmation condition for quality attributes, plays an irreplaceable role in ensuring that the collected target component meets pharmaceutical requirements in terms of purity.

[0057] Comparative Example 3 This comparative example uses the same raw materials, chromatography conditions, and online control conditions as Example 2, but the leading and trailing transition fractions after the three-stage collection are directly merged with the main peak without going through concentration, specific activity screening, and second chromatography purification steps.

[0058] The HPLC purity of the ulinastatin obtained in this comparative example was 95.2%, with a specific activity of 4510 TIU / mg protein and a total yield of 94.5%. Compared with Example 2, the yield was slightly higher, but the purity and specific activity were significantly lower, and the product could not meet the pharmaceutical grade requirements (purity ≥98%). The results indicate that the transition fraction does contain a certain amount of ulinastatin. Direct merging can improve the yield, but it will significantly reduce the product purity. This invention achieves efficient recovery of ulinastatin from the transition fraction while ensuring product purity through a closed-loop material recovery process of "concentration → specific activity screening → second chromatography purification → purity threshold merging," thus achieving the dual goals of "high purity + high yield."

[0059] Comparative Example 4 This comparative example uses the same raw materials, chromatography conditions, and online control conditions as Example 2. However, in step S6, for re-chromatographic products with unqualified purity (in this comparative example, unqualified means the purity is lower than 90% of the purity of the first-stage purified product), the termination condition of 3 cycles is not set, but the cycle continues until the purity meets the standard.

[0060] Experiments revealed that after the first and second cycles, the purity of the re-chromatographic product with unacceptable purity increased to 88% and 90.5%, respectively. After the third cycle, the purity reached 91.2%, and the rate of improvement plateaued. Continuing with the fourth and fifth cycles, the purity only increased to 91.5% and 91.6%, respectively, while signs of accumulation of impurities (especially kininogen-like substances) began to appear, and the activity recovery rate decreased from 72% in the third cycle to 58% in the fifth cycle. These results indicate that after more than three cycles, the marginal benefit of further cycling approaches zero, and the risk of impurity accumulation increases. Therefore, this invention sets the cycle termination condition to three cycles, balancing product purity and process efficiency.

[0061] Comparative Example 5 This comparative example uses the same raw materials, chromatography conditions, and online control conditions as Example 2. However, the eluent and column regeneration waste liquid generated in step S3 are not enriched by nanofiltration and reused, but are directly discharged as waste liquid; all elution buffers are freshly prepared.

[0062] The HPLC purity of the ulinastatin obtained in this comparative example was 99.1%, with a specific activity of 5080 TIU / mg protein and a total yield of 91.0%, showing no significant difference from Example 2 (p>0.05). The results indicate that the waste liquid reuse scheme does not affect the key quality attributes of the product (purity, specific activity), but significantly reduces waste liquid discharge (by approximately 40%) and the consumption of fresh buffer solution (by approximately 35%), thereby lowering production costs and aligning with the development direction of green pharmaceuticals.

[0063] The key parameters were set based on experiments. (1) Basis for determining the 12% glycosylation threshold To determine the glycosylation threshold, ulinastatin fractions with different glycosylation levels (6%, 9%, 12%, 15%, and 18%, respectively) were collected during the chromatographic elution process, and their specific activity and accelerated stability (specific activity retention rate after 14 days of storage at 40°C) were measured.

[0064] The results showed that components with a glycosylation degree <12% had an average initial specific activity of 4120 TIU / mg protein, and an average specific activity retention rate of 72% after accelerated stability testing; components with a glycosylation degree ≥12% had an average initial specific activity of 4980 TIU / mg protein, and an average specific activity retention rate of 91% after accelerated stability testing. These results indicate that a glycosylation degree ≥12% is a critical threshold for ensuring the specific activity and stability of ulinastatin. Components below this threshold not only have lower initial specific activity but also exhibit a significantly faster rate of activity decay under accelerated stability conditions, making them unsuitable as raw materials for pharmaceutical-grade products.

[0065] (2) Basis for determining the specific vitality threshold of 85% To determine the specific activity threshold for re-chromatography of transition fractions, the collected front and tail transition fractions were grouped according to their specific activity ranges (70%–75%, 75%–80%, 80%–85%, 85%–90%, and 90%–95% of the specific activity of the clarified filtrate, respectively), and then subjected to second-stage chromatography purification. The purity and activity recovery rate of the re-chromatographic products of each group were determined.

[0066] The results showed that for the group with specific activity <85%, the purity after re-chromatography was 88%–92%, and the activity recovery rate was 45%–62%, with the activity loss being irreversible during re-chromatography. For the group with specific activity ≥85%, the purity after re-chromatography was ≥94%, and the activity recovery rate was ≥78%. These results indicate that 85% is the critical threshold for determining whether a transition fraction is worth re-chromatography; fractions below this threshold experience excessive activity loss after re-chromatography, resulting in recovery costs exceeding benefits.

[0067] (3) Basis for determining the purity threshold of 90% To determine the purity threshold for merging the re-chromatographic product with the main peak, re-chromatographic products of different purities (85%, 88%, 90%, 92%, 95%) were mixed with the first-stage purified product (purity 99.2%) at the actual mass ratio, and the total purity of the mixture was determined.

[0068] The results showed that after mixing the re-chromatographic products with purities of 85% and 88% with the main peak, the total purity decreased to 96.8% and 97.5%, respectively, failing to meet the requirement of ≥98% purity for pharmaceutical-grade ulinastatin. After mixing the re-chromatographic products with a purity of 90%, the total purity was 98.3%, meeting the requirement. After mixing the re-chromatographic products with a purity ≥92%, the total purity was ≥98.5%. Using the lowest main peak purity of 99.2% as a conservative benchmark, the purity after mixing was ≥98.66% for the 99.6% case, indicating that the 90% threshold is universally applicable. Therefore, setting 90% as the combined purity threshold ensures that the final product meets the purity standard while also considering the recovery efficiency of ulinastatin in the transition fraction.

[0069] (4) Basis for determining the termination condition for the 3rd iteration To determine the appropriate number of re-chromatographic cycles to terminate, the re-chromatographic product with unacceptable purity was subjected to five consecutive re-chromatographic cycles. The purity, activity recovery rate, and residual amount of impurities (kininogen-like substances) were measured after each cycle.

[0070] The results showed that after the first cycle, purity increased to 88% and activity recovery rate was 82%; after the second cycle, purity increased to 90.5% and activity recovery rate was 76%; after the third cycle, purity increased to 91.2% and activity recovery rate was 72%; after the fourth cycle, purity only increased to 91.5% and activity recovery rate was 65%; and after the fifth cycle, purity only increased to 91.6% and activity recovery rate was 58%, with the residual amount of kininogen-like substances increasing by approximately two times compared to the third cycle. These results indicate that after more than three cycles, the improvement in purity approaches zero, while the risk of activity loss and accumulation of contaminating proteins increases significantly. Therefore, setting the cycle termination number to three times represents the optimal balance between ensuring product purity and process efficiency.

[0071] (5) Basis for determining the concentration ratio of 2 to 5 times To determine the optimal concentration factor of the transition fraction before re-chromatography, the leading and trailing transition fractions were concentrated to 1 (unconcentrated), 2, 3, 5, and 8 times their original volume, respectively. Then, re-chromatography was performed under the same chromatographic conditions, and the resolution (R_s) and activity recovery rate of each group were compared.

[0072] The results showed that without concentration, the loading volume was too large, resulting in a wide peak width and a resolution of only 1.2. Concentration to 2-fold improved the resolution to 1.6 with an activity recovery rate of 82%. Concentration to 3-fold improved the resolution to 1.8 with an activity recovery rate of 80%. Concentration to 5-fold reached a resolution of 1.9 with an activity recovery rate of 76%. Concentration to 8-fold maintained a resolution of 1.9, but the activity recovery rate significantly decreased to 58%, and protein aggregation occurred. These results indicate that concentration to 2–5-fold can maintain good resolution (R_s≥1.6) while preserving a high activity recovery rate (≥76%). Beyond 5-fold concentration, excessively high protein concentrations led to aggregation and activity loss.

[0073] The results of each embodiment and comparative example are summarized in Table 1, with specific tests and results shown below: Table 1 serial number plan Waste liquid reuse HPLC purity Specific bioactivity (TIU / mg protein) Total return Inter-batch RSD Example 1 Complete solution (including HIC) implement 99.6% 5250 89.8% 1.1% Example 2 Basic solution (without HIC) implement 99.2% 5100 91.5% 1.2% Example 3 Preferred solutions (including HIC, different parameters) implement 99.4% 5180 90.2% 1.2% Comparative Example 1 Offline manual control implement 96.8% 4680 82.3% 4.7% Comparative Example 2 UV single criterion only implement 97.5% 4820 90.8% 2.8% Comparative Example 3 Direct merge without backflow implement 95.2% 4510 94.5% 2.1% Comparative Example 4 Infinite loop implement 91.2%* — — — Comparative Example 5 No waste liquid reuse Do not execute 99.1% 5080 91.0% 1.2% *Note: Table 1 shows the purity observations at the end of the 3rd cycle (Comparative Example 4 did not have a cycle termination condition set).

[0074] As shown in Table 1, the complete scheme of this invention (Example 1) achieved excellent performance in three key indicators: purity (99.6%), specific activity (5250 TIU / mg protein), and yield (89.8%), with an inter-batch RSD as low as 1.1%. Example 3, by adjusting the hydrophobic chromatography purification parameters (ammonium sulfate concentration 1.2 mol / L, elution volume 6 column volumes), also achieved good purification results (purity 99.4%, specific activity 5180 TIU / mg protein), verifying the parameter adaptability of the preferred scheme of this invention. The basic scheme of Example 2 also meets pharmaceutical grade requirements (purity ≥98%) and is suitable for routine production. The comparative examples data verify the necessity and synergistic effect of the key technical features of this invention from different perspectives.

[0075] The above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Various changes made within the scope of knowledge possessed by those skilled in the art without departing from the concept of the present invention still fall within the scope of protection of the present invention.

Claims

1. A method for purifying ulinastatin, characterized in that, Includes the following steps: S1: The crude extract of ulinastatin is subjected to microfiltration to remove suspended solids and macromolecular impurities, resulting in a clear filtrate; S2: The clarified filtrate is concentrated by ultrafiltration, and the pH and conductivity of the retentate are monitored online in real time. When the pH and conductivity of the retentate simultaneously meet the loading parameter requirements of anion exchange chromatography, the concentration is stopped to obtain the chromatographic loading solution. S3: Load the chromatographic loading solution onto anion exchange chromatography medium, and use a pH-salt concentration dual gradient stepwise elution method to remove impurity protein components in stages, and then collect the ulinastatin target component after elution. During the elution process, the UV absorbance data at the column outlet is collected in real time, and its first and second derivatives are calculated. The start point, peak apex, and end point of the elution peak are determined in real time based on the rate of change of the first and second derivatives. At the same time, the glycosylation degree data of the eluent is detected online periodically on the time scale of the elution peak. When the start point has been determined and the glycosylation degree reaches the preset glycosylation degree threshold, the collection of the target component is initiated. When the termination point is determined, data collection stops. S4: Taking the start of target component collection in step S3 as the starting point of main peak collection and the termination point as the ending point of main peak collection, the main peak eluent is collected as the first-stage purified product. The eluent from the starting point to the main peak collection point is collected separately as the leading transition fraction, and the eluent from the ending point to the point where the absolute value of the first derivative is continuously lower than the third preset threshold for more than 3 sampling periods is collected separately as the tail transition fraction. S5: The leading transition fraction and the tail transition fraction are concentrated respectively, and the specific activity of ulinastatin in the concentrate is measured. When the specific activity is not lower than the preset specific activity threshold, the fraction is purified by chromatography under the second chromatography conditions, and the leading re-chromatographic product and the tail re-chromatographic product are collected respectively. S6: Detect the purity of the frontal re-chromatographic product and the tail re-chromatographic product. When the purity of both is not lower than the preset purity threshold, combine the first-stage purified product, the frontal re-chromatographic product and the tail re-chromatographic product to obtain pure ulinastatin. Otherwise, the re-chromatographic product with unqualified purity is used as the raw material for step S5 and purified by chromatography again. If the purity is still unqualified after three consecutive re-chromatographic purifications, the product is discarded.

2. The method for purifying ulinastatin according to claim 1, characterized in that, The loading parameters for the anion exchange chromatography in step S2 are as follows: pH value 5.0-5.5, conductivity 8-12 mS / cm; the ultrafiltration adopts a constant pressure operation mode with an operating pressure of 0.15-0.25 MPa and a molecular weight cutoff of 10-30 kDa for the ultrafiltration membrane.

3. The method for purifying ulinastatin according to claim 1, characterized in that, Step S3, specifically the pH-salt concentration dual-gradient stepwise elution, includes three stages: The first stage of impurity removal involves elution with an acetate-sodium acetate buffer solution at a pH of 5.0–5.5 and a sodium chloride concentration of 0.05–0.1 mol / L to remove the first type of impurities. The second stage of impurity removal involves elution with an acetate-sodium acetate buffer solution at a pH of 4.2–4.8 and a sodium chloride concentration of 0.15–0.2 mol / L to remove the second type of impurities. The third stage of collection: Elution was performed using an acetate-sodium acetate buffer solution with a pH of 3.5–4.0 and a sodium chloride concentration of 0.3–0.5 mol / L, and the eluent of the ulinastatin target peak was collected.

4. The method for purifying ulinastatin according to claim 1, characterized in that, The glycosylation threshold mentioned in step S3 is 12%.

5. The method for purifying ulinastatin according to claim 1, characterized in that, The second chromatography conditions in step S5 are as follows: the sample loading amount is 30% to 150% of the sample loading amount of the chromatography loading solution described in step S3, and the elution volume of each stage is 50% to 100% of the elution volume of the corresponding stage in step S3.

6. The method for purifying ulinastatin according to claim 1, characterized in that, The preset specific activity threshold in step S5 is 85% of the specific activity of ulinastatin in the clarified filtrate; the concentration treatment increases the concentration of ulinastatin to 2 to 5 times the original concentration.

7. The method for purifying ulinastatin according to claim 1, characterized in that, The first-stage purified product collected in step S4 is purified by hydrophobic chromatography: after adjusting the ammonium sulfate concentration to 1.2-1.5 mol / L, it is loaded onto phenyl agarose gel chromatography medium and eluted using a gradient desalting method. The active elution peak of ulinastatin is collected and replaced with this active elution peak for the merging operation in step S6.

8. The method for purifying ulinastatin according to claim 1, characterized in that, The method also includes combining the eluent containing impurities generated in step S3 (elution to remove impurities) with the column regeneration waste liquid, enriching ulinastatin in the eluent through a nanofiltration membrane, and returning the enriched solution to the clarified filtrate from step S1 for recycling; the nanofiltration membrane has a molecular weight cutoff of 3-5 kDa; the nanofiltration permeate is desalted by reverse osmosis and used to prepare the elution buffer for step S3.

9. The method for purifying ulinastatin according to claim 1, characterized in that, The preset purity threshold in step S6 is 90% of the purity of the first-stage purified product; the purity is the peak area normalized purity measured by high performance liquid chromatography.

10. The method for purifying ulinastatin according to claim 1, characterized in that, The method for determining the starting point, peak, and ending point in step S3 is as follows: when the first derivative increases from a value less than a first preset threshold to a positive value greater than the first preset threshold, and the second derivative is greater than a second preset threshold, it is determined to be the starting point; when the first derivative decreases from a positive value to a negative value, and the second derivative is less than 0, it is determined to be the peak; when the first derivative increases from a negative value less than a third preset threshold to a value greater than the third preset threshold, and the second derivative changes from a negative value to a positive value, it is determined to be the ending point; wherein, the sampling frequency of the ultraviolet absorbance is 2 to 10 times / second.

Citation Information

Patent Citations

  • Method for purifying ulinastatin by adsorption column chromatography

    CN103073637B

  • A hydrophobic column-based purification method for ulinastatin

    CN107827976B

  • Method for purifying ulinastatin based on affinity chromatography column

    CN108059670A

  • A chromatographic peak recognition method based on convolutional neural network

    CN111767790B

  • Purification method of ulinastatin and ulinastatin product

    CN116355078A